Source: Annual Congress 2010 - Nocturnal cardiology: chronic heart failure, acute chest syndrome, coronary artery disease and collagen vascular disease
Disease area: Sleep and breathing disorders

Abstract

Aim: Obstructive sleep apnea syndrome (OSAS) is associated cardiovascular abnormalities including left ventricular dysfunction. N-terminal fraction of brain natriuretic peptide (NT-proBNP) is a hormone which may reflect the severity of underlying cardiac dysfunction and be elevated levels have been associated with diminished left ventricular functional capacity. The aim of present study is evaluate whether NT-proBNP is related to OSAS and the effect of continuous positive airway pressure (CPAP) therapy. Materials and methods: Thirty seven patients who were referred to our sleep disorders center with a suspicion of OSAS were consecutively included in the study. Exclusion criteria included cardiovascular diseases. The subjects were examined with polysomnography (PSG) and classified as controls according to data of the apnea-hypopnea index (AHI<5). All patients with OSAS were also diagnosed with PSG (AHI≥5). All cases underwent NT-proBNP measurement. Results: Serum NT-proBNP levels were significantly higher in OSAS group (n=20) than control group (n=17) (p=0.03). We showed that in OSAS patients serum NT-proBNP levels were decreased after 4 weeks of CPAP treatment (p=0.005). Conclusion: NT-proBNP levels reflect underlying cardiac dysfunction associated with OSAS.

Rating:

Share or cite this content

Citations should be made in the following way:
E. Gecgil, T. Ulukavak Ciftci, O. Kokturk, Y. Tavil (Ankara, Turkey). NT-pro BNP is a marker for cardiovascular dysfunction due to obstructive sleep apnea syndrome. Eur Respir J 2010; 36: Suppl. 54, 917

Member's Comments

No comment yet.

Related content which might interest you: BNP or VEGF levels do not predict disease severity in obstructive sleep apnoea syndrome (OSAS) Source: Eur Respir J 2005; 26: Suppl. 49, 40s Year: 2005 Relationship between plasma NT-proBNP level and cardiovascular complications in obstructive sleep apnoea (OSA) patients Source: Annual Congress 2010 - Nocturnal cardiology: chronic heart failure, acute chest syndrome, coronary artery disease and collagen vascular disease Year: 2010 Relationship between NT-proBNP level, echocardiographic parameters and cardiovascular diseases in patients with obstructive sleep apnoea (OSA) Source: Annual Congress 2012 - Physiology, obesity and the downstream effects of OSA Year: 2012 NT-proBNP in obstructive sleep apnoea (OSA) Source: Eur Respir J 2006; 28: Suppl. 50, 415s Year: 2006 Cardiovascular diseases are responsible for increased plasma NT-proBNP level in obstructive sleep apnoea (OSA) patients Source: Annual Congress 2012 - Physiology, obesity and the downstream effects of OSA Year: 2012 Brain natriuretic peptide levels in the obstructive sleep apnoea/hypopnoea syndrome Source: Eur Respir J 2005; 26: Suppl. 49, 355s Year: 2005 Cardiac troponin I levels and relationship with cardiovascular morbidity in patients with obstructive sleep apnea syndrome Source: Eur Respir J 2005; 26: Suppl. 49, 38s Year: 2005 Vasopressin, atrial natriuretic peptide and adrenomedullin as markers of hypoxic stress in patients with obstructive sleep apnoea syndrome Source: Annual Congress 2013 –Heart, blood and metabolism in sleep disordered breathing Year: 2013 Relationship between NT-proBNP plasma level and nocturia in obstructive sleep apnoea (OSA) patients Source: Annual Congress 2007 - Systemic effects of obstructive sleep apnoea Year: 2007 Comparison of plasma NT-proBNP level in overlap syndrome (obstructive sleep apnoea + chronic obstructive pulmonary disease) and obstructive sleep apnoea (OSA) Source: Annual Congress 2008 - Control of breathing and respiratory disorders during sleep Year: 2008 S100B protein: A useful marker in obstructive sleep apnea syndrome Source: Annual Congress 2012 - Clinical predictors of OSA, adherence to CPAP and psychology Year: 2012 Endothelial dysfunction in patients with obstructive sleep apnea independent of metabolic syndrome Source: Annual Congress 2008 - Cardiovascular complications in obstructive sleep apnoea Year: 2008 Leukocytosis as a marker of chronic inflammation and early cardiovascular risk in patients with obstructive sleep apnea syndrome Source: Eur Respir J 2007; 30: Suppl. 51, 593s Year: 2007 Association between severe obstructive sleep apnea syndrome and sinus dysfunction Source: Annual Congress 2007 - Sleep apnoea in cardiorespiratory disorders Year: 2007 Markers of liver dysfunction in patients with obstructive sleep apnea Source: Annual Congress 2011 - Obstructive sleep apnoea: inflammation and metabolism Year: 2011 Myocardial alterations in asymptomatic patients with obstructive sleep apnea syndrome Source: International Congress 2017 – Obstructive and central sleep apnoea: consequences and comorbidities Year: 2017 Cystatin C and albuminuria as markers of kidney and cardiovascular diseases in obstructive sleep apnoea syndrome (OSAS) Source: Annual Congress 2012 - Metabolic and cardiovascular consequences of OSA II Year: 2012 The prevalance of cardiovascular disorders in patients with obstructive sleep apnoea syndrome Source: Eur Respir J 2002; 20: Suppl. 38, 293s Year: 2002 Plasma orexin-A levels in patients with obstructive sleep apnea syndrome Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea Year: 2007 Elevated c-reactive protein in patients with obstructive sleep apnea hypopnea syndrome (OSAH) Source: Annual Congress 2007 - Systemic effects of obstructive sleep apnoea Year: 2007